Company
Electrocore
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
8
510(k), De Novo and PMA
Device trials
19
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.
Listed
ECOR
Nasdaq · electroCore, Inc.
Public float
$28.0M
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$32.0M
Fiscal year ending Dec 31, 2025
Net income
-$14.0M
Fiscal year ending Dec 31, 2025
R&D spending
$2.4M
Fiscal year ending Dec 31, 2024
Cash
$6.3M
As of Sep 30, 2026
Long-term debt
$7.9M
As of Sep 30, 2026
Shares outstanding
9.2M
As of Oct 30, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2025 | – | – | $7.5M | – |
| 2023 | – | $8.1M | – | – |
Private placements (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
Company details
From the company's latest Form D.
- Legal name
- electroCore, Inc.
- Headquarters
- Rockaway, New Jersey
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1560258 ↗
Executives, directors and promoters
As listed on the latest Form D.
9 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
- gammaCore Sapphire510(k)
K211856 · Decided Sep 10, 2021 · 86 days after receipt
Device type: Non-Invasive Vagus Nerve Stimulator - Headache (PKR) · Neurology & Neurosurgery
- gammaCore Sapphire510(k)
K203546 · Decided Feb 12, 2021 · 70 days after receipt
Device type: Non-Invasive Vagus Nerve Stimulator - Headache (PKR) · Neurology & Neurosurgery
- gammaCore Sapphire510(k)
K191830 · Decided Mar 26, 2020 · 261 days after receipt
Device type: Non-Invasive Vagus Nerve Stimulator - Headache (PKR) · Neurology & Neurosurgery
5 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Non-invasive Vagus Nerve Stimulation for the Prevention of MigrainesPivotal-lookingCompleted
NCT03716505 · 231 participants · Start Nov 2, 2018 · Primary completion Sep 9, 2020
Device: gammaCore Sapphire active; gammaCore Sapphire Sham · For: Migraine Disorders
Sites: Scottsdale, Arizona; Carlsbad, California; Palo Alto, California · 30 sites in all
- Non-invasive Neurostimulation of the Vagus Nerve for the Treatment of Cluster HeadachePivotal-lookingCompleted
NCT01792817 · 150 participants · Start Feb 2013 · Primary completion Jun 2014
Device: GammaCore; Sham GammaCore device · For: Cluster Headache
Sites: Santa Monica, California; Stanford, California; Englewood, Colorado · 20 sites in all
- A Randomized, Sham-controlled Study of gammaCore ® (nVNS) for Prevention of Episodic MigrainePivotal-lookingCompleted
NCT02378844 · 477 participants · Start Jun 2015 · Primary completion Feb 1, 2018
Device: gammaCore®-R; gammaCore®-R Sham · For: Migraine
Sites: Liège, Belgium; Glostrup Municipality, Denmark; Berlin, Germany · 22 sites in all
16 more trials with a free account
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.